Gergana Galabova

USPTO Granted Patents = 8 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 7.1

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

Years Active: 2015-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12290553 - Method for vaccination against a self-antigen in a human patient (2025-05-06),

2. 11980657 - Peptide vaccines for hypercholesterolemia related diseases (2024-05-14),

3. 10933123 - Peptide vaccines usable for hypercholesterolemia related diseases (2021-03-02),

4. 10004791 - Peptide vaccines against PCSK9 (2018-06-26),

5. 9999659 - Treatments using a peptide and/or vaccine (2018-06-19),

6. 9669079 - PCSK9 peptide combination vaccine and method of use (2017-06-06),

7. 9533030 - Vaccine capable of inducing formation of antibodies directed to proprotein convertase subtilisin/kexin type 9 (PCSK9) in vivo (2017-01-03),

8. 9220762 - PCSK9 peptide combination vaccine and method of use (2015-12-29),

Title: Gergana Galabova: Pioneering Innovations in Vaccine Development

Introduction: Gergana Galabova is a prominent inventor based in Vienna, Austria, renowned for her significant contributions to the field of vaccine development. With an impressive portfolio of eight patents, she has been instrumental in advancing methods for combating diseases through innovative therapeutic strategies.

Latest Patents: Among her latest patents, Gergana has developed a method for vaccination against a self-antigen in human patients. This groundbreaking methodology involves administering an effective dose of a self-antigen aimed at eliciting a primary immune response. What sets her approach apart is the subsequent boost administration of the self-antigen, with a higher quantity compared to the initial dose, enhancing the immune response. Additionally, her work on peptide vaccines for hypercholesterolemia-related diseases focuses on a vaccine that induces the formation of antibodies targeting PCSK9 in vivo, showcasing her commitment to addressing critical health issues.

Career Highlights: Gergana has made significant strides in her career, working with well-regarded companies in the biopharmaceutical industry. Notable among them are Affiris AG and Affiris CVD GmbH, where she has contributed her expertise to advancing vaccine technologies. Her innovative spirit and dedication to research have established her as a key contributor in her field.

Collaborations: Throughout her career, Gergana has collaborated with talented professionals, including esteemed colleagues Sylvia Brunner and Gabriele Winsauer. These collaborations have not only enhanced her research but have also provided a platform for knowledge exchange and mutual growth within the scientific community.

Conclusion: Gergana Galabova continues to push the boundaries of vaccine innovation, with her latest patents reflecting a deep understanding of immunology and therapeutic development. As a leading figure in her domain, her work will undoubtedly leave a lasting impact on the healthcare industry, paving the way for new strategies in disease prevention and treatment.

This text is generated by artificial intelligence and may not be accurate.